PTEN and RB1 are frequently codeleted in late-stage human prostate cancer, including castration-resistant prostate adenocarcinoma and treatment-emergent neuroendocrine prostate cancer (13, 14, 40, 50, 51). This evidence concerns the gene PTEN and prostate carcinoma.